News

Filter

Current filters:

Replagal

EMA approves Shire Vpriv plant in USA

23-02-2012

Ireland-headquartered biopharma firm Shire (LSE: SHP) says that the European Medicines Agency's Committee…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShireVpriv

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv

01-09-2011

Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

FDA advisory panel backs approval of Shire’s Firazyr for HAE; Replagal site cleared by EMA

27-06-2011

In a decision that was largely expected given positive briefing papers by US Food and Drug Administration…

BiotechnologyFirazyrNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShire

Shire presents new data for Replagal and VPRIV; gets PUDFA date for Firazyr

22-03-2011

Ireland-headquartered biopharma company Shire (LSE: SHP) presented new data for Replagal (agalsidase…

FirazyrPharmaceuticalRare diseasesRegulationReplagalResearchShireVpriv

COMPANY SPOTLIGHT

Menarini

Back to top